Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey.
dermatologists
methotrexate
practice survey
psoriasis
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
15
04
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
To evaluate the modalities of methotrexate prescription for moderate to severe psoriasis by dermatologists in France. We performed a national online practice survey between October and December 2020. A total of 254 dermatologists responded, 237 reported prescribing methotrexate for moderate to severe psoriasis in adults, of which 57% as a first line systemic treatment. Nineteen percent reported performing a test dose at the initiation of treatment. Methotrexate was prescribed orally in 54.7% of cases, subcutaneously in 44.8% of cases and intramuscularly in 0.4% of cases. The initial weekly dose of methotrexate was <15 mg for 30% of the dermatologists and ≥15 mg for 70% of them. Two hundred and three dermatologists had already change the route of administration for methotrexate from the oral to injectable form due to poor tolerance (48.3%), lack of efficacy (35%) or lack of compliance (16.7%). Two hundred thirty-four dermatologists (98.7%) reported prescribing folic acid with methotrexate, and 79.3% reported prescribing tests evaluating the risk of hepatic fibrosis. Forty-three percent of dermatologists have not initiated or have reduced their prescriptions since the beginning of the pandemic of COVID-19. Prescribing patterns were different according to the type of practice (private practice versus hospital/mixed practice). Methotrexate is used by the majority of dermatologists interviewed for moderate to severe psoriasis in adults, with heterogeneity of practices.
Identifiants
pubmed: 33935509
doi: 10.2147/CCID.S311269
pii: 311269
pmc: PMC8079246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
389-393Informations de copyright
© 2021 Fougerousse et al.
Déclaration de conflit d'intérêts
Funding source: Nordic Pharma laboratory. Dr Anne-Claire Fougerousse report grants from NORDIC Pharma, during the conduct of the study; Dr Josiane Parier reports personal fees from Medac, personal fees from Janssen, personal fees from Novartis, personal fees from Amgen, personal fees from Leo Pharma, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Br J Dermatol. 2016 Jul;175(1):23-44
pubmed: 27484275
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679
pubmed: 32564417
Vaccines (Basel). 2020 Dec 16;8(4):
pubmed: 33339348
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:12-8
pubmed: 21388454
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1967-1971
pubmed: 29569785
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):224-231
pubmed: 24731093
Arch Dermatol Res. 2011 Jan;303(1):1-10
pubmed: 20857129
J Am Acad Dermatol. 2020 Jun;82(6):1445-1486
pubmed: 32119894
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):464-483
pubmed: 30793796
Ann Dermatol Venereol. 2019 Feb;146(2):106-114
pubmed: 30704943
J Dermatolog Treat. 2017 Nov;28(7):631-634
pubmed: 28489482
Br J Dermatol. 2014 Jul;171(1):17-29
pubmed: 24606161
Acta Derm Venereol. 2016 Jan;96(1):23-8
pubmed: 25721372
Br J Dermatol. 2021 Apr;184(4):765-767
pubmed: 33220078